TG-0054

DRUG2 trials

Sponsors

GPCR Therapeutics, Inc.

Conditions

HealthyHodgkin's DiseaseMultiple MyelomaNon-hodgkin's Lymphoma

Phase 1

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

CompletedNCT00822341

GPCR Therapeutics, Inc.Healthy

Start: 2008-04-30End: 2009-05-31Updated: 2021-08-04

Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

CompletedNCT01458288

GPCR Therapeutics, Inc.Hodgkin's Disease, Multiple Myeloma, Non-hodgkin's Lymphoma

Start: 2012-10-31End: 2013-07-31Updated: 2021-04-19